{"nct_id":"NCT02964507","title":"Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer","status":"TERMINATED","status_verified_date":"2024-08","start_date":"2019-09-26","start_date_type":"ACTUAL","primary_completion_date":"2020-09-29","primary_completion_date_type":"ACTUAL","completion_date":"2021-07-19","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["GSK"]}